Evolus (EOLS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

EOLS Stock Forecast

Evolus stock forecast is as follows: an average price target of $24.00 (represents a 120.39% upside from EOLS’s last price of $10.89) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

EOLS Price Target

The average price target for Evolus (EOLS) is $24.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $27.00 to $20.00. This represents a potential 120.39% upside from EOLS's last price of $10.89.

EOLS Analyst Ratings

Buy

According to 4 Wall Street analysts, Evolus's rating consensus is 'Buy'. The analyst rating breakdown for EOLS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Evolus Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 03, 2024	Douglas Tsao	H.C. Wainwright	$27.00	$17.05	58.40%	147.93%
Sep 13, 2024	Balaji Prasad	Barclays	$20.00	$16.46	21.51%	83.65%
Sep 13, 2024	Vamil Divan	Mizuho Securities	$25.00	$16.46	51.88%	129.57%
Jan 29, 2024	Balaji Prasad	Barclays	$16.00	$13.47	18.78%	46.92%

The latest Evolus stock forecast, released on Oct 03, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $27.00, which represents a 58.40% increase from the stock price at the time of the forecast ($17.05), and a 147.93% increase from EOLS last price ($10.89).

Evolus Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	4
Avg Price Target	-	$27.00	$22.00
Last Closing Price	$10.89	$10.89	$10.89
Upside/Downside	-100.00%	147.93%	102.02%

In the current month, the average price target of Evolus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Evolus's last price of $10.89. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 13, 2024	Needham	Buy	Buy	Hold
Sep 13, 2024	Barclays	Overweight	Overweight	Hold
Jan 29, 2024	Barclays		Overweight	Upgrade
Jan 17, 2024	Needham	Buy	Buy	Hold
Jan 17, 2024	Cantor Fitzgerald	Buy	Buy	Hold
Jun 24, 2022	Needham		Buy	Initialise

Evolus's last stock rating was published by H.C. Wainwright on Oct 03, 2024. The company gave EOLS a "Buy" rating, the same as its previous rate.

Evolus Financial Forecast

Evolus Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Revenue	-	-	-	-	-	-	-	-	$59.33M	$49.32M	$48.68M	$41.72M	$43.65M	$33.90M	$37.16M	$33.91M	$34.66M	$26.68M	$26.10M	$12.24M	$20.58M	$17.66M	$7.81M	$10.50M	$19.45M	$13.17M	$2.31M
Avg Forecast	$105.81M	$84.43M	$81.95M	$75.38M	$76.78M	$63.17M	$64.93M	$57.27M	$60.19M	$44.35M	$49.30M	$40.57M	$43.89M	$36.00M	$36.60M	$29.83M	$34.76M	$25.41M	$24.67M	$11.11M	$21.20M	$11.51M	$1.93M	$15.24M	$18.02M	$3.97M	$341.17K
High Forecast	$106.30M	$84.82M	$82.34M	$75.73M	$77.87M	$63.57M	$64.93M	$57.27M	$60.33M	$44.35M	$49.53M	$40.76M	$44.10M	$36.00M	$36.60M	$29.83M	$34.76M	$25.41M	$24.67M	$11.11M	$21.20M	$11.51M	$1.93M	$15.24M	$18.02M	$3.97M	$341.17K
Low Forecast	$105.43M	$84.12M	$81.66M	$75.11M	$75.99M	$62.78M	$64.93M	$57.27M	$60.05M	$44.35M	$49.12M	$40.43M	$43.73M	$36.00M	$36.60M	$29.83M	$34.76M	$25.41M	$24.67M	$11.11M	$21.20M	$11.51M	$1.93M	$15.24M	$18.02M	$3.97M	$341.17K
# Analysts	1	1	1	1	3	1	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3
Surprise %	-	-	-	-	-	-	-	-	0.99%	1.11%	0.99%	1.03%	0.99%	0.94%	1.02%	1.14%	1.00%	1.05%	1.06%	1.10%	0.97%	1.53%	4.04%	0.69%	1.08%	3.32%	6.77%

Evolus's average Quarter revenue forecast for Mar 24 based on 4 analysts is $57.27M, with a low forecast of $57.27M, and a high forecast of $57.27M. EOLS's average Quarter revenue forecast represents a -3.48% decrease compared to the company's last Quarter revenue of $59.33M (Dec 23).

Evolus EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	1	1	3	1	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3
EBITDA	-	-	-	-	-	-	-	-	$-25.21M	$-19.37M	$-20.05M	$-10.57M	$-9.45M	$-16.80M	$-18.52M	$-14.35M	$-2.49M	$-18.02M	$-13.38M	$9.24M	$-105.98M	$-6.82M	$-16.84M	$-15.10M	$-10.53M	$-23.30M	$-34.10M
Avg Forecast	$-63.64M	$-50.78M	$-49.29M	$-45.34M	$-46.18M	$-38.00M	$-39.06M	$-22.98M	$-36.20M	$-26.67M	$-29.65M	$-20.89M	$-15.71M	$-23.01M	$-23.39M	$-18.99M	$-22.21M	$-16.24M	$-15.76M	$-7.10M	$-13.55M	$-7.36M	$-1.23M	$-11.01M	$-11.52M	$-2.54M	$-218.00K
High Forecast	$-63.41M	$-50.60M	$-49.11M	$-45.17M	$-45.70M	$-37.76M	$-39.06M	$-18.39M	$-36.12M	$-26.67M	$-29.54M	$-16.71M	$-12.57M	$-23.01M	$-23.39M	$-15.19M	$-22.21M	$-16.24M	$-15.76M	$-7.10M	$-13.55M	$-7.36M	$-1.23M	$-8.81M	$-11.52M	$-2.54M	$-218.00K
Low Forecast	$-63.94M	$-51.02M	$-49.52M	$-45.55M	$-46.83M	$-38.23M	$-39.06M	$-27.58M	$-36.29M	$-26.67M	$-29.79M	$-25.07M	$-18.85M	$-23.01M	$-23.39M	$-22.79M	$-22.21M	$-16.24M	$-15.76M	$-7.10M	$-13.55M	$-7.36M	$-1.23M	$-13.21M	$-11.52M	$-2.54M	$-218.00K
Surprise %	-	-	-	-	-	-	-	-	0.70%	0.73%	0.68%	0.51%	0.60%	0.73%	0.79%	0.76%	0.11%	1.11%	0.85%	-1.30%	7.82%	0.93%	13.64%	1.37%	0.91%	9.19%	156.42%

4 analysts predict EOLS's average Quarter EBITDA for Jun 21 to be $-15.76M, with a high of $-15.76M and a low of $-15.76M. This is -270.52% lower than Evolus's previous annual EBITDA (Mar 21) of $9.24M.

Evolus Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	1	1	3	1	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3
Net Income	-	-	-	-	-	-	-	-	$-11.83M	$-16.92M	$-18.14M	$-14.79M	$-13.16M	$-20.28M	$-23.47M	$-17.50M	$-18.18M	$-19.43M	$-15.60M	$6.40M	$-110.69M	$-11.46M	$-21.13M	$-19.73M	$-14.51M	$-26.98M	$-37.57M
Avg Forecast	$1.58M	$-4.10M	$-1.26M	$1.58M	$1.26M	$-7.79M	$-3.32M	$-28.07M	$-7.81M	$-14.05M	$-15.97M	$-25.52M	$-21.64M	$-19.29M	$-16.41M	$-23.20M	$-14.07M	$-17.03M	$-16.31M	$8.84M	$-16.39M	$-25.01M	$-46.97M	$-14.38M	$-49.20M	$-72.68M	$-60.57M
High Forecast	$1.59M	$-4.09M	$-1.26M	$1.59M	$25.26M	$-7.75M	$-3.30M	$-22.46M	$-5.58M	$-13.98M	$-15.89M	$-20.41M	$-17.31M	$-19.29M	$-16.41M	$-18.56M	$-14.07M	$-17.03M	$-16.31M	$10.61M	$-16.39M	$-25.01M	$-46.97M	$-11.51M	$-49.20M	$-72.68M	$-60.57M
Low Forecast	$1.57M	$-4.13M	$-1.27M	$1.57M	$-21.47M	$-7.84M	$-3.34M	$-33.68M	$-10.05M	$-14.14M	$-16.07M	$-30.62M	$-25.97M	$-19.29M	$-16.41M	$-27.84M	$-14.07M	$-17.03M	$-16.31M	$7.07M	$-16.39M	$-25.01M	$-46.97M	$-17.26M	$-49.20M	$-72.68M	$-60.57M
Surprise %	-	-	-	-	-	-	-	-	1.51%	1.20%	1.14%	0.58%	0.61%	1.05%	1.43%	0.75%	1.29%	1.14%	0.96%	0.72%	6.76%	0.46%	0.45%	1.37%	0.29%	0.37%	0.62%

Evolus's average Quarter net income forecast for Jun 21 is $-16.31M, with a range of $-16.31M to $-16.31M. EOLS's average Quarter net income forecast represents a -354.78% decrease compared to the company's last Quarter net income of $6.40M (Mar 21).

Evolus SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	1	1	3	1	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3
SG&A	-	-	-	-	-	-	-	-	$43.06M	$43.33M	$41.17M	$37.38M	$36.73M	$34.79M	$36.88M	$33.44M	$33.28M	$31.68M	$26.47M	$20.68M	$27.39M	$21.94M	$17.55M	$33.05M	$31.75M	$32.10M	$35.87M
Avg Forecast	$166.84M	$133.13M	$129.23M	$118.86M	$121.07M	$99.61M	$102.39M	$53.95M	$94.91M	$69.93M	$77.74M	$63.98M	$69.21M	$56.77M	$57.72M	$47.03M	$54.81M	$40.07M	$38.90M	$17.52M	$33.43M	$18.15M	$3.05M	$24.03M	$28.42M	$6.26M	$537.96K
High Forecast	$167.62M	$133.75M	$129.83M	$119.42M	$122.78M	$100.23M	$102.39M	$64.74M	$95.13M	$69.93M	$78.10M	$64.28M	$69.54M	$56.77M	$57.72M	$47.03M	$54.81M	$40.07M	$38.90M	$17.52M	$33.43M	$18.15M	$3.05M	$24.03M	$28.42M	$6.26M	$537.96K
Low Forecast	$166.24M	$132.65M	$128.76M	$118.43M	$119.82M	$99.00M	$102.39M	$43.16M	$94.70M	$69.93M	$77.46M	$63.74M	$68.96M	$56.77M	$57.72M	$47.03M	$54.81M	$40.07M	$38.90M	$17.52M	$33.43M	$18.15M	$3.05M	$24.03M	$28.42M	$6.26M	$537.96K
Surprise %	-	-	-	-	-	-	-	-	0.45%	0.62%	0.53%	0.58%	0.53%	0.61%	0.64%	0.71%	0.61%	0.79%	0.68%	1.18%	0.82%	1.21%	5.76%	1.38%	1.12%	5.13%	66.68%

Evolus's average Quarter SG&A projection for Mar 24 is $53.95M, based on 4 Wall Street analysts, with a range of $43.16M to $64.74M. The forecast indicates a 25.30% rise compared to EOLS last annual SG&A of $43.06M (Dec 23).

Evolus EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	1	1	3	1	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3
EPS	-	-	-	-	-	-	-	-	$-0.00	$-0.30	$-0.00	$-0.26	$-0.23	$-0.36	$-0.42	$-0.31	$-0.33	$-0.35	$-0.31	$0.17	$-3.28	$-0.34	$-0.63	$-0.59	$-0.47	$-0.98	$-1.37
Avg Forecast	$0.03	$-0.07	$-0.02	$0.03	$0.02	$-0.12	$-0.05	$-0.15	$-0.12	$-0.22	$-0.25	$-0.19	$-0.17	$-0.31	$-0.26	$-0.34	$-0.22	$-0.27	$-0.26	$-0.47	$-0.26	$-0.40	$-0.75	$-0.64	$-0.78	$-1.16	$-0.97
High Forecast	$0.03	$-0.06	$-0.02	$0.03	$0.40	$-0.12	$-0.05	$-0.15	$-0.09	$-0.22	$-0.25	$-0.19	$-0.17	$-0.31	$-0.26	$-0.34	$-0.22	$-0.27	$-0.26	$-0.47	$-0.26	$-0.40	$-0.75	$-0.64	$-0.78	$-1.16	$-0.97
Low Forecast	$0.02	$-0.07	$-0.02	$0.02	$-0.34	$-0.12	$-0.05	$-0.15	$-0.16	$-0.22	$-0.25	$-0.19	$-0.17	$-0.31	$-0.26	$-0.34	$-0.22	$-0.27	$-0.26	$-0.47	$-0.26	$-0.40	$-0.75	$-0.64	$-0.78	$-1.16	$-0.97
Surprise %	-	-	-	-	-	-	-	-	0.00%	1.35%	0.00%	1.40%	1.37%	1.17%	1.61%	0.91%	1.47%	1.29%	1.19%	-0.37%	12.56%	0.85%	0.84%	0.92%	0.60%	0.85%	1.42%

According to 4 Wall Street analysts, Evolus's projected average Quarter EPS for Jun 21 is $-0.26, with a low estimate of $-0.26 and a high estimate of $-0.26. This represents a -252.94% decrease compared to EOLS previous annual EPS of $0.17 (Mar 21).

Evolus Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PROC	Procaps Group	$3.69	$10.00	171.00%
EOLS	Evolus	$11.73	$24.00	104.60%	Buy
AMPH	Amphastar Pharmaceuticals	$40.85	$66.00	61.57%	Buy
ANIP	ANI Pharmaceuticals	$55.83	$79.00	41.50%	Buy
COLL	Collegium Pharmaceutical	$30.90	$42.33	36.99%	Buy
ALKS	Alkermes	$30.75	$37.50	21.95%	Hold
PCRX	Pacira BioSciences	$19.83	$23.75	19.77%	Hold
PBH	Prestige Consumer Healthcare	$80.39	$89.50	11.33%	Buy
ITCI	Intra-Cellular Therapies	$86.96	$93.33	7.33%	Buy
SUPN	Supernus Pharmaceuticals	$36.22	$36.00	-0.61%	Buy
PAHC	Phibro Animal Health	$22.34	$18.67	-16.43%	Buy

EOLS Forecast FAQ

Is Evolus a good buy?

Yes, according to 4 Wall Street analysts, Evolus (EOLS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of EOLS's total ratings.

What is EOLS's price target?

Evolus (EOLS) average price target is $24 with a range of $20 to $27, implying a 120.39% from its last price of $10.89. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Evolus stock go up soon?

According to Wall Street analysts' prediction for EOLS stock, the company can go up by 120.39% (from the last price of $10.89 to the average price target of $24), up by 147.93% based on the highest stock price target, and up by 83.65% based on the lowest stock price target.

Can Evolus stock reach $20?

EOLS's average twelve months analyst stock price target of $24 supports the claim that Evolus can reach $20 in the near future.

What are Evolus's analysts' financial forecasts?

Evolus's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $262.15M (high $263.63M, low $260.97M), average EBITDA is $-146M (high $-141M, low $-152M), average net income is $-37.909M (high $-8.247M, low $-66.324M), average SG&A $377.03M (high $390.14M, low $364.36M), and average EPS is $-0.308 (high $0.0738, low $-0.67). EOLS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $347.58M (high $349.2M, low $346.31M), average EBITDA is $-209M (high $-208M, low $-210M), average net income is $-2.21M (high $-2.166M, low $-2.258M), average SG&A $548.06M (high $550.63M, low $546.07M), and average EPS is $-0.035 (high $-0.0343, low $-0.0358).

Did the EOLS's actual financial results beat the analysts' financial forecasts?

Based on Evolus's last annual report (Dec 2023), the company's revenue was $199.72M, beating the average analysts forecast of $194.41M by 2.73%. Apple's EBITDA was $-70.208M, missing the average prediction of $-113M by -38.10%. The company's net income was $-61.685M, missing the average estimation of $-63.35M by -2.63%. Apple's SG&A was $164.94M, missing the average forecast of $306.55M by -46.19%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-0.785 by -99.86%. In terms of the last quarterly report (Dec 2023), Evolus's revenue was $59.33M, missing the average analysts' forecast of $60.19M by -1.43%. The company's EBITDA was $-25.206M, missing the average prediction of $-36.204M by -30.38%. Evolus's net income was $-11.831M, beating the average estimation of $-7.815M by 51.39%. The company's SG&A was $43.06M, missing the average forecast of $94.91M by -54.63%. Lastly, the company's EPS was $-0.0002, missing the average prediction of $-0.124 by -99.84%